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A B S T R A C T
Background. – Antidepressants are frequently prescribed in patients with psychotic disorders, but little
is known about their effects in routine clinical practice. The objective was to investigate the prescribing
patterns of antidepressants in relation to the course of depressive symptoms in patients with psychotic
disorders.
Methods. – A cohort of 214 Dutch patients with psychotic disorders received two assessments of
somatic and psychiatric health, including a clinician-rated screening for depressive symptoms, as part of
annual routine outcome monitoring.
Results. – Depressive symptoms were prevalent among 43% (93) of the patients. Antidepressants were
prescribed for 40% (86) of the patients and the majority 83% (71) continued this therapy after one year.
Multivariable analysis showed that patients with more severe psychopathology had a higher risk to
develop depressive symptoms the following year (OR [95% CI] = 0.953 [0.912–0.995]). For patients with
depressive symptoms at baseline, polypharmacy was a potential risk factor to keep having depressive
symptoms (OR [95% CI] = 1.593 [1.123–2.261]). Antidepressant use was not an independent predictor in
both analyses.
Conclusions. – Routine outcome monitoring in patients with psychotic disorders revealed a high
prevalence of depressive symptoms. Antidepressants were frequently prescribed and continued in
routine clinical practice.
 2010 Elsevier Masson SAS. All rights reserved.1. Introduction
Depressive symptoms occur in about 25% of patients with
schizophrenia [10,44], but the reported prevalence may vary
between 7 and 75% [15,19,20,26]. The variation is due to
heterogeneous study populations, differences in study methods
and differences in diagnostic criteria. Depressive symptoms may be
present throughout all phases of schizophrenia [7,26]. The highest
prevalence is found during acute psychotic episodes [23]. Persistent
depressive symptoms during the chronic phase of illness have been
associated with a higher risk for relapses [9,39]. Depressive
symptoms may reﬂect a psychological reaction to the severe illness
or ‘demoralization syndrome’ [34] or can partly mimic extrapyra-
midal side effects related to the dopamine blockade of antipsycho-* Corresponding author. Tel.: +31 50 3638205; fax: +31 50 3632772.
E-mail address: k.taxis@rug.nl (K. Taxis).
0924-9338/$ – see front matter  2010 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.eurpsy.2010.10.007tics, known as ‘akinetic depression’ or dysphoria [18,20,46].
Antipsychotic-induced depressive symptoms may be treated by
lowering the antipsychotic dose, switching to another (atypical)
antipsychotic or adding anticholinergic medication [30,44].
Guidelines for the treatment of schizophrenia advise prescrib-
ing antidepressants for depressive symptoms [3,32,45], although
there is conﬂicting evidence on the efﬁcacy of antidepressants for
depressive symptoms in schizophrenia from randomized con-
trolled clinical trials [28,47]. Antidepressants are prescribed for
11 to 43% of the patients with schizophrenia [5,25,36]. They are
commonly used to treat depressive symptoms, but may also be
used for anxiety disorders or negative symptoms [14,38,42].
Adding antidepressants to antipsychotics increases the risk of
interaction and side effects [33], and may also lead to higher
medical costs.
Longitudinal observational studies describing predictors for the
development or persistence of depressive symptoms in patients
with schizophrenia are scarce. Moreover, longitudinal studies
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of prescribing patterns of antidepressant therapy [4,12,35,39]. It is
unclear how many patients with persistent depressive symptoms
continue to use antidepressants or remain untreated with anti-
depressants. The current naturalistic study is based on a cohort of
patients with schizophrenia or related psychotic disorders, assessed
during yearly routine outcome measurements. The aim is to
investigate the course of depressive symptoms in relation to
prescribing patterns of antidepressants in schizophrenia during one-
year follow-up.
2. Methods
All patients of 18 years and older with schizophrenia or related
psychotic disorders covered by a mental health care centre in a
circumscribed area in The Netherlands were included in yearly
routine outcome assessments of their physical and mental health
as described previously [40,41]. Assessments were carried out
between January 2003 and April 2006 in patients having given
informed consent in accordance with the latest version of the
Declaration of Helsinki. Patients were included if they completed
a ﬁrst (baseline) and second assessment (follow-up) within an
interval of 12 months (3 months). In-patients with an acute
psychosis at ﬁrst assessment were excluded from analysis. Trained
nurses conducted a structured interview lasting approximately one
hour to evaluate the patients’ social functioning, mental and physical
health status. Current medication use was retrieved from the
patient’s medical records and was then conﬁrmed with the patient. A
psychiatrist based the diagnosis on the Diagnostic and Statistical
Manual of Mental Disorders-4th edition (DSM-IV) classiﬁcation
system (codes 295.4–295.9, 297.1, 298.8 and 298.9) [13]. The
patient’s psychiatrist rated depressive and extrapyramidal symp-
toms on a 3-point Likert scale (absent, moderate, severe) and
assessed psychosocial functioning using the Global Assessment of
Functioning scales (GAF-symptoms and GAF-disability).
Patients with moderate or severe depressive symptoms were
categorized as ‘having depressive symptoms’. Baseline character-
istics were compared (a) between patients who did not have
depressive symptoms at both assessments and patients who
developed depressive symptoms at second assessment (‘inci-
dence’); (b) between patients with depressive symptoms at
baseline that were no longer present at second assessment
(‘remitted’) and patients with depressive symptoms present at
both assessments (‘persistent’).Table 1
A comparison of relevant variables of the total population at baseline (n = 473).
Study sample (n = 214) 
Gender, female (%; n) 43 (92) 
Age (mean; SD) 38.7 (11.7) 
Duration of illness (mean; SD) 12.2 (9.4) 
Diagnosis (%; n) 
Schizophrenia 76 (162) 
Schizoaffective 20 (43) 
Psychotic disorder NOS 4 (9) 
Treatment status (%; n) 
Outpatients 64 (138) 
Sheltered housing facilities 21 (44) 
Chronic in-patients 15 (32) 
Symptomatology (mean; SD)
GAF-symptoms 65.6 (15.1) 
GAF-disability 61.0 (16.0) 
Depressive symptoms (%; n) 43 (93) 
Antidepressants (%; n) 40 (86) 
n: number; SD: standard deviation; NOS: not otherwise speciﬁed; GAF: global assessme
continuous variables by a Mann-Whitney U test.We analyzed potential predictors of depressive symptoms at
follow-up. As a ﬁrst step we compared baseline characteristics
between patients with and without depressive symptoms at
follow-up in a univariable analysis. Categorical variables were
tested using a Chi2 test and continuous variables were not
normally distributed and were therefore assessed by the non-
parametric Mann-Whitney U test. Multivariable logistic regres-
sion analysis was used to identify baseline patient character-
istics as independent predictors of the incidence or the
persistence of depressive symptoms at follow-up. Only those
baseline characteristics with a signiﬁcance level of P < 0.25 in
the univariable analysis were entered as predictors in the model.
Signiﬁcance levels greater than 0.05 are commonly applied to
select predictors for multivariable analysis [29]. In the multi-
variable analysis, a probability level of P < 0.05 was accepted as
statistically signiﬁcant. All P-values are two-sided. In a more
detailed description of the prescribing patterns of antidepres-
sants, the course of depressive symptoms was compared
between patients not using antidepressants at both assessments
and patients who used antidepressants at both assessments by
calculating the conﬁdence intervals for these groups.
3. Results
A total of 473 patients were eligible for inclusion into the study.
Of those, 34% (162) did not want to participate in a second
assessment or were lost to follow-up, e.g. moved away. Twenty-
one percent (97) of the patients had their second assessment not
within 9 to 15 months. The remaining 45% (214) patients with a
period of 11.8 months (SD 1.7) between ﬁrst and second
assessment were included in the study. The mean age was
38.7 years (SD 11.7; range 16–65 years) and mean duration of
illness was 12.2 years (SD 9.4; range 1–44 years); 43% (92) were
female, 76% (162) suffered from schizophrenia and the majority
were outpatients (Table 1). Patients included in the study did not
differ from the 259 not-included patients regarding age, duration
of illness and prevalence of depressive symptoms at baseline. The
proportion of females and outpatients was somewhat higher in the
group of included patients, as was the proportion of patients using
antidepressants and the average GAF-scores. Depressive symp-
toms were present among 43% (93) of the patients included and
antidepressants were prescribed for 40% (86) patients, of whom
83% (71) continued their antidepressant therapy.
Univariable analysis showed that depressive symptoms at
follow-up were potentially associated with the following baselineNot included (n = 259) Chi2 or Z-value P-value
34 (88) x2 = 4.04 0.044
39.6 (12.6) Z = 1.14 0.255
11.1 (9.8) Z = 1.25 0.211








59.0 (18.5) Z = 5.02 0.000
56.4 (16.4) Z = 4.22 0.000
37 (97) x2 = 1.76 0.185
27 (69) x2 = 8.89 0.003
nt of functioning. Categorical variables were analyzed by a two-sided Chi2 test and
Table 2
Baseline characteristics of patients with and without depressive symptoms at follow-up (n = 214).
No depressive symptoms (n = 136) Depressive symptoms (n = 78) Chi2 or Z-value P-value
Gender, female (%; n) 46 (62) 38 (30) x2 = 1.03 0.311
Age (mean; SD) 38.4 (12.2) 39.4 (11.0) Z = 0.69 0.489
Duration of illness (mean; SD) 11.6 (9.6) 13.3 (8.9) Z = 1.63 0.103
Diagnosis (%; n) x2 = 3.04 0.219
Schizophrenia 76 (103) 76 (59)
Schizoaffective 18 (25) 23 (18)
Psychotic disorder NOS 6 (8) 1 (1)
Treatment status (%; n) x2 = 0.56 0.756
Outpatients 66 (90) 62 (48)
Living in sheltered housing facilities 19 (26) 23 (18)
Chronic in-patients 15 (20) 15 (12)
Psychosocial status (%; n)
No daytime activities 29 (36) 24 (18) x2 = 0.58 0.447
No contact with friends 31 (42) 21 (16) x2 = 2.70 0.100
No contact with family 12 (16) 6 (5) x2 = 1.61 0.205
Symptomatology (mean; SD)
GAF-symptoms 66.9 (15.9) 63.4 (13.2) Z = 1.58 0.113
GAF-disability 61.3 (16.9) 60.4 (14.3) Z = 0.75 0.454
Extrapyramidal symptoms (%; n) 15 (20) 18 (14) x2 = 0.39 0.532
Depressive symptoms 29 (40) 68 (53) x2 = 29.96 0.000
Antipsychotics (%; n) x2 = 3.29 0.349
Atypical antipsychotics 69 (94) 62 (48)
Typical antipsychotics 10 (14) 13 (10)
Combination atypical + typical 10 (14) 18 (14)
No antipsychotics 10 (14) 8 (6)
Number of drugs prescribed (mean; SD) 2.4 (1.6) 3.3 (2.3) Z = 2.81 0.005
Number of drugs prescribed; excl.antidepr. 2.0 (1.4) 2.8 (2.2) Z = 2.41 0.016
Antidepressants (%; n) 35 (47) 50 (39) x2 = 4.92 0.027
Anticholinergics 4 (5) 9 (7) x2 = 2.63 0.105
Benzodiazepines 32 (43) 40 (31) x2 = 1.45 0.229
Moodstabilizers 13 (17) 14 (11) x2 = 0.11 0.738
Type of antidepressant (%; n) x2 = 1.10 0.576
Selective serotonin reuptake inhibitors 60 (28) 62 (24)
Tricyclic antidepressants 17 (8) 23 (9)
Other antidepressants 23 (11) 15 (6)
n: number; SD: standard deviation; NOS: not otherwise speciﬁed; GAF: global assessment of functioning; excl.antidepr.: exclusive antidepressants; anticholinergics included
biperiden, dexetimide and trihexyphenidyl. Categorical variables were analyzed by a two-sided Chi2 test and continuous variables by a Mann-Whitney U test.
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no contact with friends or family, GAF-symptoms, depressive
symptoms at baseline, antidepressant use, number of drugs other
than antidepressants, use of benzodiazepines and anticholinergics
(Table 2). These variables, except for use of benzodiazepines and
anticholinergics being covered by the number of other drugs than
antidepressants, were entered into a multivariable analysis to
identify independent predictors of either the incidence or the
persistence of depressive symptoms at follow-up.
Of the 121 patients without depressive symptoms at baseline,
79% (96) remained free of symptoms and 21% (25) patients newly
developed depressive symptoms at second assessment (Table 3).
Patients with a lower GAF-symptom score at baseline had a higherTable 3
Course of depressive symptoms and antidepressant therapy between baseline and foll
Baseline n Follow-up 
No depressive symptoms
Antidepressants 42 No depressive symptoms 
Incidence of depressive symptom
No antidepressants 79 No depressive symptoms 
Incidence of depressive symptom
Depressive symptoms
Antidepressants 44 Remitted from depressive symp
Persistent depressive symptoms
No antidepressants 49 Remitted from depressive symp
Persistent depressive symptoms
n = number; changes in antidepressant prescription between baseline and follow-up were
but discontinued their therapy before the second assessment) or ‘started’ (patients w
assessment).risk of developing depressive symptoms (n = 121, odds ratio [95%
conﬁdence intervals] = 0.953 [0.912–0.995], P < 0.030), when
adjusting for the subset of clinical and sociodemographic
characteristics as mentioned above. Of the 93 patients with
depressive symptoms at baseline, 43% (40) ‘remitted’ (i.e. were free
of depressive symptoms at second assessment) and 57% (53) had
‘persistent’ depressive symptoms after one year. Prescription of a
higher number of drugs at baseline was a risk factor to have
persistent depressive symptoms at follow-up (n = 93, OR
[CI] = 1.593 [1.123–2.261], P < 0.009).
The course of depressive symptoms in relation to antidepressant
therapy is illustrated in Table 3. Of the patients without depressive
symptoms at ﬁrst assessment, 35% (42/121) were prescribedow-up (n = 214).
n Antidepressant prescription n
32 Discontinued 7
s 10 Discontinued 1
64 Started 5
s 15 Started 4
toms 15 Discontinued 4
 29 Discontinued 3
toms 25 Started 4
 24 Started 4
 indicated by ‘discontinued’ (patients who used antidepressants at ﬁrst assessment,
ho did not use antidepressants at ﬁrst assessment, but started before the second
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these 34 patients, 26% (9/34; CI: 12–49%) developed symptoms
despite antidepressant therapy (incidence). The remaining 65% (79)
patients without depressive symptoms at ﬁrst assessment were
prescribed no antidepressants; 70 of them did not start antide-
pressants between ﬁrst and second assessment. The incidence rate
in the latter group was 16% (11/70; CI: 7–30%). Of the patients with
depressive symptoms at ﬁrst assessment, 47% (44/93) were
prescribed antidepressants; 37 of them continued their antidepres-
sants at follow-up. Seventy percent (26/37; CI: 56–85%) of them had
persisting depressive symptoms despite continuing antidepres-
sants, of whom only four switched type of antidepressants at second
assessment. Of the patients with depressive symptoms at ﬁrst
assessment, 53% (49) did not use antidepressants and 41 of them did
not start antidepressants between ﬁrst and second assessment. The
percentage of patients with persistent depressive symptoms was
49% (20/41; CI: 33–64%).
4. Discussion
This naturalistic study showed a high prevalence rate (43%)
of depressive symptoms in patients with psychotic disorders.
Although the modal prevalence rate reported in the meta-
analysis by Siris and Bench was 25% [44], the ﬁndings were in
line with comparable studies [4,12]. Previous cross-sectional
studies have shown that depressive symptoms are associated
with more severe psychopathology and (related) polypharmacy
[8,12,24,27,31,43]. Our longitudinal study showed that these
patient characteristics are also predictors of depressive symp-
toms. Patients with more severe psychopathology had a higher
risk to develop depressive symptoms the following year. For
patients with depressive symptoms at baseline, polypharmacy
was a potential risk factor to keep having depressive symptoms.
Also in accordance with previous studies, depressive symptoms
were not associated with age, gender, duration of illness or
being institutionalized [1,2,7,8,12,31,37]. Antidepressant use at
baseline was related to the presence of depressive symptoms at
follow-up in univariable analysis. However, multivariable
analysis indicated that antidepressant use was neither an
independent predictor of remaining symptom free, nor of
remitting from depressive symptoms.
Antidepressants were frequently prescribed in routine clinical
practice as in previous studies [6,12,15,31]. Our study brought
new insight into the prescribing patterns of antidepressants in
relation to the course of depressive symptoms. The majority of
antidepressants were continued once prescribed. A large
proportion of patients appeared to have persistent depressive
symptoms despite continuation of antidepressant treatment.
Patients’ symptoms may have remitted and reoccurred at second
assessment or they may be non-responders. Another group
continued antidepressants even though they remained free of
depressive symptoms both years. Their antidepressant therapy
may have served as an effective prophylaxis [16,21], for other
indications such as negative symptoms or anxiety or it may
indicate overprescribing. In contrast, a considerable proportion
of patients did not receive antidepressants despite experiencing
persistent depressive symptoms, which may suggest under-
prescribing.
The prescribing patterns may reﬂect the state of guidelines for
schizophrenia. Current schizophrenia guidelines recommend to
use antidepressants in patients with depressive symptoms, but do
not give detailed prescribing advice, in particular about discontin-
uation in non-responders and duration of maintenance therapy
[32,45]. Some guidelines refer for prescription of antidepressants
to the depression guideline [3], although it is doubtful whether
depressive symptoms in schizophrenia should be treated the sameway as major depressive disorder. One of the reasons for the lack of
detail in the guidelines is the scarcity of evidence about
effectiveness of antidepressants in schizophrenia [28,47], but also
for depression in general [22]. More placebo-controlled research
into the effectiveness of antidepressants is needed for the
development and improvement of guidelines for prescription of
antidepressants in schizophrenia.
Our study has the following limitations. Firstly, we cannot
make ﬁrm conclusions regarding the effectiveness of antidepres-
sants given the limitations of the naturalistic approach of the
current study. This approach may give rise to ‘confounding by
indication’ as in all observational research, i.e. patients using
antidepressants may be more severely ill and thus would be more
likely to have recurrent or persistent depressive symptoms. This is
(partly) corrected for in our logistic regression. Other possible
confounders in the apparent lack of antidepressant effect could
have been poor compliance, prescription of inadequate doses in
patients with antidepressants, or non-pharmacological treat-
ments such as psychotherapy in patients without antidepres-
sants. Secondly, depressive symptoms were clinician-rated
instead of by a depression instrument validated for schizophrenia.
We therefore cannot be sure whether the clinicians adequately
distinguished depressive symptoms from negative symptoms.
Thirdly, long-term follow-up is considered difﬁcult in patients
with schizophrenia [4,11], but we achieved a reasonable response
rate of 45%. Our study sample differed from the patients who were
not included in male/female ratio and level of functioning. The
higher proportion of females in our study sample may explain the
higher number of outpatients and the higher GAF-scores, as well
as the increased use of antidepressants [6,17,31]. Despite these
differences, the comparison of our ﬁndings with earlier studies as
discussed above suggest that our sample is overall representative
of a population with schizophrenia and related psychotic
disorders. Lastly, depressive symptoms are known for their
waxing and waning over time [12]. We measured symptoms once
a year as part of our routine outcome monitoring, but a shorter
time frame may be needed to follow patients with depressive
symptoms.
In conclusion, our ﬁndings indicate that depressive symptoms
occur frequently in clinical practice patients. We also found high
prescription rates of antidepressants, and most patients continued
their antidepressant medication once prescribed. Patients with
more severe psychopathology had a higher risk to develop
depressive symptoms the following year. For patients with
depressive symptoms at baseline, polypharmacy was a potential
risk factor to keep having depressive symptoms. We therefore
would recommend close monitoring of the treatment in patients
with depressive symptoms, in particular in those patients with
predictors present.
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